A review on newly approved PARP inhibitors: Talazoparib and Olaparib
This project report is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2024.
Main Author: | Karim, Azrin |
---|---|
Other Authors: | Islam, Farzana |
Format: | Project report |
Language: | English |
Published: |
Brac University
2024
|
Subjects: | |
Online Access: | http://hdl.handle.net/10361/24372 |
Similar Items
-
A review on potential of PARP inhibitors in the treatment of prostate cancer
by: Islam, Saidul
Published: (2022) -
Association of XRCC1 and XPD polymorphism with risk of prostate cancer in Bangladesh population
by: Ahmed, Nafisa
Published: (2023) -
SHP2 inhibitors: Recent advancements and potential breakthroughs in cancer therapy
by: Meem, Manila
Published: (2023) -
Mutation in DNA polymerase γ: mitochondrial disorders
by: Hossain, Sadman Sanjid
Published: (2023) -
RIPK pathway, as a potential target, for cancer treatment - a review
by: Jahan, Nusrat
Published: (2024)